In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13,…
The program for the upcoming PFF Summit 2015: From Bench to Bedside has been announced by the Pulmonary Fibrosis Foundation (PFF), the organizer of the event. The third biennial international healthcare conference on pulmonary fibrosis (PF) will take place between November 12 and 14 in Washington, D.C., and will…
ProMetic Life Sciences, Inc., a biopharmaceutical company focused on plasma-derived therapeutics and small-molecule drug development, recently announced that its product PBI-4050 for the treatment of idiopathic pulmonary fibrosis (IPF) has been granted orphan drug designation status by the European Commission. IPF is a progressive fatal lung disease of unknown…
A new study published in the journal Respiratory Research revealed that an enzyme called matrix metalloproteinase 10 may be a suitable novel biomarker for idiopathic pulmonary fibrosis (IPF). The study was led by researchers at the Kyoto University in Japan and is entitled “Matrix metalloproteinase-10:…
MediciNova Inc., a biopharmaceutical company focused on small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced the start of a Phase 2 study on its product MN-001 (tipelukast) as treatment for patients with a diagnosis of moderate to severe idiopathic pulmonary fibrosis (IPF). IPF…
ProMetic Life Sciences, Inc., a biopharmaceutical corporation active in the development of novel therapeutic products targeting unmet medical needs in several fields, including fibrosis, is pleased to announce it recently concluded a successful Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational anti-fibrotic…
Results from phase III trials with Esbriet® (pirfenidone), a drug developed by Roche, were recently presented at the European Respiratory Society (ERS) congress held in Amsterdam from September 26-30, 2015. The results revealed that Esbriet® is beneficial for long-term treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is characterized by progressive…
A team of researchers from The Netherlands recently discovered that talc (magnesium silicate), often used in the food industry, is a danger to health and exposure to it should be closely monitored. The study findings were recently presented by Dr. Jos Rooijackers, a pulmonologist from the Netherlands Expertise Centre for…
In a new study entitled “BARD1 mediates TGF-β signaling in pulmonary fibrosis”, researchers investigated whether the tumor suppressor gene BARD1, previously shown to have a role in lung cancer, is associated with pulmonary fibrosis. They found that TGF-beta, an established factor in promoting fibrosis, induces BARD1 protein expression…
New data from the analysis of trial INPULSIS™-ON, describing the long-term efficacy and side-effects of OFEV in the treatment of idiopathic pulmonary fibrosis (IPF), was presented at the European Respiratory Society (ERS) International Congress 2015. IPF is a type of interstitial lung disease, affecting the tissue that supports the alveoli…
Get regular updates to your inbox.
